Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × BI 2536 × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Sarcoma 1 Other hematologic neoplasm 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 177 Prednisone 132 Gemcitabine 132 pembrolizumab 109 enzalutamide 104 Abiraterone Acetate 97 Nivolumab 93 Magnetic Resonance Spectroscopy 93 Cisplatin 89 Radiotherapy 86 Leuprolide 85 Sunitinib 80 Carboplatin 75 Specimen Handling 64 Radiosurgery 59 Paclitaxel 57 Androgen Antagonists 56 Goserelin 55 Ipilimumab 52 bicalutamide 51 apalutamide 50 Sorafenib 48 Bevacizumab 47 cabozantinib 45 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 Everolimus 42 cabazitaxel 41 abiraterone 41 durvalumab 38 atezolizumab 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00706498 2014-05-16

Phase II Study of BI 2536 in Prostate Cancer

Boehringer Ingelheim

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡